Absorption, distribution, metabolism and excretion of londamocitinib after single-dose inhaled, intravenous and oral administration in healthy participants.
AIM Londamocitinib (AZD4604) is an inhaled, selective Janus kinase 1 (JAK1) inhibitor in development for asthma. This open-label, two-part, phase I clinical study (NCT06157255) used a radiolabelled microtracer approach to evaluate the absolute bioavailability and the absorption, distribution, metabolism and excretion (...